ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) rose 8.3% on Wednesday . The stock traded as high as $2.50 and last traded at $2.47. Approximately 1,505,606 shares were traded during mid-day trading, an increase of 8% from the average daily volume of 1,392,085 shares. The stock had previously closed at $2.28.
Separately, BidaskClub raised ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. ZIOPHARM Oncology currently has an average rating of “Hold” and a consensus target price of $5.25.
The stock has a market capitalization of $337.44 million, a price-to-earnings ratio of -4.66 and a beta of 1.85.
Several hedge funds and other institutional investors have recently modified their holdings of ZIOP. BlackRock Inc. boosted its position in shares of ZIOPHARM Oncology by 8.5% in the second quarter. BlackRock Inc. now owns 9,167,740 shares of the biotechnology company’s stock worth $27,686,000 after buying an additional 717,804 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of ZIOPHARM Oncology in the first quarter worth about $911,000. UBS Group AG boosted its position in shares of ZIOPHARM Oncology by 35.3% in the first quarter. UBS Group AG now owns 872,376 shares of the biotechnology company’s stock worth $3,420,000 after buying an additional 227,812 shares during the period. Bank of America Corp DE boosted its position in shares of ZIOPHARM Oncology by 198.1% in the second quarter. Bank of America Corp DE now owns 99,565 shares of the biotechnology company’s stock worth $301,000 after buying an additional 201,063 shares during the period. Finally, Vident Investment Advisory LLC boosted its position in shares of ZIOPHARM Oncology by 46.8% in the second quarter. Vident Investment Advisory LLC now owns 587,255 shares of the biotechnology company’s stock worth $1,774,000 after buying an additional 187,195 shares during the period. 39.32% of the stock is owned by institutional investors.
About ZIOPHARM Oncology (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Featured Story: Do Tariffs Work?
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.